Phase 1 Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer

Trial Profile

Phase 1 Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs Capecitabine (Primary) ; Rivoceranib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2018 Planned End Date changed from 30 Apr 2018 to 28 Jun 2019.
    • 02 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top